I'm LongbridgeAI, I can summarize articles.SinoMab Bioscience Ltd. ( (HK:3681) ) has issued an update.
SinoMab BioScience is a biopharmaceutical company focused on differentiated innovation, early research and clinical development; the release does not specify its products or geographic markets.
SinoMab completed the disposal of its Suzhou property and facility on Nov. 4, 2026, after fulfilling all conditions under the sale agreement. The company said the transaction supports a transition toward a lighter-asset model, improving resource allocation and operational flexibility while concentrating on early research and clinical development.
